HK1087327A1 - Modified natriuretic compounds, conjugates, and uses thereof - Google Patents

Modified natriuretic compounds, conjugates, and uses thereof

Info

Publication number
HK1087327A1
HK1087327A1 HK06107556.5A HK06107556A HK1087327A1 HK 1087327 A1 HK1087327 A1 HK 1087327A1 HK 06107556 A HK06107556 A HK 06107556A HK 1087327 A1 HK1087327 A1 HK 1087327A1
Authority
HK
Hong Kong
Prior art keywords
conjugates
compounds
disclosed
natriuretic
modified
Prior art date
Application number
HK06107556.5A
Other languages
English (en)
Inventor
Kenneth D James
Balasingam Radhakrishnan
Navdeep B Malkar
Mark A Miller
Nnochiri N Ekwuribe
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of HK1087327A1 publication Critical patent/HK1087327A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
HK06107556.5A 2002-11-26 2006-07-04 Modified natriuretic compounds, conjugates, and uses thereof HK1087327A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42915102P 2002-11-26 2002-11-26
PCT/US2003/037996 WO2004047871A2 (fr) 2002-11-26 2003-11-12 Composes natriuretiques modifies, leurs conjugues et leur utilisation

Publications (1)

Publication Number Publication Date
HK1087327A1 true HK1087327A1 (en) 2006-10-13

Family

ID=32393512

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107556.5A HK1087327A1 (en) 2002-11-26 2006-07-04 Modified natriuretic compounds, conjugates, and uses thereof

Country Status (13)

Country Link
US (1) US7662773B2 (fr)
EP (1) EP1569683B1 (fr)
JP (1) JP2006515579A (fr)
CN (1) CN100558398C (fr)
AT (1) ATE459370T1 (fr)
AU (2) AU2003297583B2 (fr)
BR (1) BR0316560A (fr)
CA (1) CA2504287A1 (fr)
DE (1) DE60331584D1 (fr)
HK (1) HK1087327A1 (fr)
PL (1) PL377813A1 (fr)
SG (1) SG159387A1 (fr)
WO (1) WO2004047871A2 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
WO2004022003A2 (fr) 2002-09-06 2004-03-18 University Of South Florida Substances et procedes servant a traiter des maladies allergiques
WO2004022579A2 (fr) * 2002-09-06 2004-03-18 University Of South Florida Apport cellulaire de peptides natriuretiques
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
CA2504287A1 (fr) 2002-11-26 2004-06-10 Nobex Corporation Composes natriuretiques modifies, leurs conjugues et leur utilisation
EP1660047B1 (fr) 2003-08-13 2013-11-27 Biocon Limited Formulation de dosage de solides de sels d'acides gras destinee a des agents therapeutiques
CA2559853A1 (fr) * 2004-02-17 2005-10-13 University Of South Florida Materiaux et methodes permettant de traiter des troubles inflammatoires et lies a la proliferation cellulaire
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
DE602005026014D1 (de) 2004-07-15 2011-03-03 Univ Queensland Proteinartige verbindungen und anwendungen davon
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
US7300494B2 (en) * 2005-02-24 2007-11-27 Hamilton Sundstrand Corporation On-board inert gas generation system with compressor surge protection
PL2510942T3 (pl) 2005-04-07 2016-02-29 Cardiorentis Ag Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
RS53847B1 (en) 2005-07-29 2015-08-31 Nektar Therapeutics PROCEDURES FOR OBTAINING POLYMER REAGENTS
WO2007035600A2 (fr) * 2005-09-16 2007-03-29 Mayo Foundation For Education And Research Activités natriurétiques
WO2007047834A2 (fr) * 2005-10-18 2007-04-26 Biocon Limited Conjugués de peptides pour administration par voie orale pour traiter des maladies métaboliques
WO2007115182A2 (fr) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Constructions linéaires de peptides natriurétiques
JP5355383B2 (ja) 2006-03-30 2013-11-27 パラティン・テクノロジーズ・インコーポレーテッド 環状ナトリウム利尿ペプチド構築物
EP2051585A4 (fr) * 2006-04-28 2010-06-02 Univ South Florida Matieres et procedes destines a reduire une inflammation par inhibition du recepteur du peptide natriuretique auriculaire
US8486635B2 (en) 2006-05-30 2013-07-16 Mayo Foundation For Medical Education And Research Detecting and treating dementia
EP2687223B1 (fr) 2006-05-30 2017-07-12 Mayo Foundation For Medical Education And Research Detection et traitement de la démence
WO2007143561A1 (fr) 2006-06-01 2007-12-13 Mayo Foundation For Medical Education And Research Immunité vis-a-vis des récepteurs de folate
WO2008088582A2 (fr) 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Méthodes et substances associées à des isoformes trail
CN101600731A (zh) 2006-09-08 2009-12-09 梅约医学教育与研究基金会 不具备血管舒张活性的促排水和利尿钠多肽
BRPI0811052A2 (pt) 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
TWI367213B (en) 2007-11-21 2012-07-01 Biomarin Pharm Inc Variants of c-type natriuretic peptide
WO2009156481A1 (fr) * 2008-06-25 2009-12-30 Ascendis Pharma As Bnp pégylé
WO2010033217A1 (fr) 2008-09-19 2010-03-25 Nektar Therapeutics Conjugués polymères de peptides cd-np
WO2010033207A1 (fr) 2008-09-19 2010-03-25 Nektar Therapeutics Conjugués polymères de peptides thérapeutiques
BRPI1012783B1 (pt) 2009-05-20 2021-09-21 Biomarin Pharmaceutical Inc Variantes de peptídeo natriurético tipo c (cnp), seu método de produção recombinante e seu uso, composição farmacêutica e composição para tratamento de uma condição ou distúrbio responsivo a cnp
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
MX2012001024A (es) 2009-07-23 2012-04-11 Igisu Co Ltd Composicion de preparaciones externas para la piel.
US9018348B2 (en) 2010-04-27 2015-04-28 Agency For Science, Technology And Research eIF4E binding peptides
WO2012013597A1 (fr) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Substances et utilisation desdites substances pour influer sur les récepteurs peptidiques natriurétiques
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
CN107261119A (zh) 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
KR20140054084A (ko) 2011-08-19 2014-05-08 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US20130244937A1 (en) 2011-09-02 2013-09-19 Nile Therapeutics, Inc. Chimeric natriuretic peptide compositions and methods of preparation
WO2013058833A1 (fr) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprenant une phosphatase alcaline et/ou un peptide natriurétique et leurs procédés d'utilisation
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
CN104364378A (zh) * 2012-03-19 2015-02-18 麦德林制药私人有限公司 制备重组肽的方法
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
WO2016007873A1 (fr) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions et méthodes de traitement de la craniosynostose
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP4014987A3 (fr) 2015-05-29 2022-07-06 Igisu Co., Ltd. Peptide cyclique et médicament, préparation à usage externe et produit cosmétique contenant tous ledit peptide cyclique
EP3337894A1 (fr) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Fabrication de phosphatases alcalines
WO2017058822A1 (fr) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp)
EP3368062A4 (fr) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la craniosynostose chez un patient
EP3400021A1 (fr) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Agonistes de cnp à libération contrôlée présentant une faible liaison à npr-c
EP3400022A1 (fr) * 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Agonistes de cnp à libération contrôlée avec faible activité npr-b initiale
PL3400019T3 (pl) * 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
AU2017205268B2 (en) 2016-01-08 2022-02-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
IL259659B (en) 2016-01-08 2022-08-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
CA3008017C (fr) * 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Agonistes de cnp a liberation controlee presentant des effets secondaires reduits
EP3426286A4 (fr) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez l'enfant
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
EP3464573A4 (fr) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Impact du métal sur la production des phosphatases alcalines
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
WO2018089601A1 (fr) 2016-11-09 2018-05-17 Mayo Foundation For Medical Education And Research Analogues de manp
WO2018175534A1 (fr) * 2017-03-22 2018-09-27 Pharmain Corporation Agonistes npra, compositions et utilisations correspondantes
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
US11547760B2 (en) 2017-09-05 2023-01-10 Torque Therapeutics, Inc. Reversible linkers and use thereof
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
JP7216332B2 (ja) 2018-03-20 2023-02-01 日油株式会社 分岐型単分散ポリエチレングリコール、中間体およびその製造方法
WO2019190752A1 (fr) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Production de glycoprotéines
KR102022118B1 (ko) * 2019-01-07 2019-09-18 주식회사 아스트로젠 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물
CN110278941B (zh) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液
CN111848776B (zh) * 2020-08-31 2022-03-18 江苏璟泽生物医药有限公司 聚乙二醇修饰的rhBNP及其制备方法
CN111978390B (zh) * 2020-08-31 2022-10-14 上海景泽生物技术有限公司 聚乙二醇修饰的rhBNP及其用途
WO2023039392A1 (fr) * 2021-09-07 2023-03-16 Mayo Foundation For Medical Education And Research Procédés et matériaux pour déterminer un dosage cible de pgc
CN114316020A (zh) * 2021-12-28 2022-04-12 南京岚煜生物科技有限公司 一种bnp重组蛋白及其制备方法和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1983000150A1 (fr) * 1981-07-02 1983-01-20 Walton, Alan, G. Complexe medicamenteux de glycosaminoglycan
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5037741A (en) * 1986-08-18 1991-08-06 The Coca Cola Company Enzymatic method for the synthesis and separation of peptides
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
CA1339210C (fr) 1988-05-31 1997-08-05 John Lewicki Techniques recombinantes pour la production de nouveaux natriuretiques et de peptides vasodilatateurs
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
JP2539665B2 (ja) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 神経疾患治療剤
JP2561513B2 (ja) 1988-07-04 1996-12-11 塩野義製薬株式会社 γ−ＡＮＰを認識するモノクローナル抗体
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IT1229514B (it) 1989-01-30 1991-09-03 Farmhispania S A A Montme Glicoconiugati anfifilici sintetici per impiego neurologico.
ATE124994T1 (de) 1989-03-01 1995-07-15 Daiichi Pure Chemicals Co Ltd Physiologisch aktives polypeptid und dna.
US20020086843A1 (en) 1989-03-01 2002-07-04 Daiichi Pure Chemicals Co., Ltd. Physiologically active polypeptide and DNA
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
EP0479948B1 (fr) 1989-06-23 1998-08-26 Genentech, Inc. Compositions et procedes destines a la synthese du recepteur b de la proteine natriuretique et procede d'utilisation
US5108568A (en) * 1989-07-07 1992-04-28 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
SE8904407L (sv) 1989-12-29 1991-06-30 Qingpingfeng Medikament foer behandling av hjaertsvikt
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US5853746A (en) 1991-01-31 1998-12-29 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier
ATE253639T1 (de) 1991-08-19 2003-11-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von peptiden
JP2665850B2 (ja) * 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
CA2188143A1 (fr) 1992-12-09 1995-11-02 Wolf-Georg Forssmann Utilisation de peptides natriuretiques du cerveau (bnp), d'urodilatine phosphorylee, de cdd/anp phosphoryle et de leurs combinaisons
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
WO1995006467A1 (fr) 1993-08-28 1995-03-09 The University Of Sheffield Traitement de la fourbure
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
NO319913B1 (no) * 1994-12-09 2005-10-03 Shionogi & Co Fremgangsmate til sandwichimmunoassay for N-peptid
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
NZ322686A (en) 1995-10-19 2000-01-28 Univ Washington Discrete-length polyethene glycols
EP2292662B1 (fr) * 1996-03-04 2014-04-23 Scios Inc. Analyses et reactifs permettant de quantifier le hBNP
JP4847634B2 (ja) 1996-03-22 2011-12-28 ストライカー・コーポレーション 中枢神経系の虚血または外傷の機能的回復を増大させる方法
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
EP0939770A1 (fr) 1996-10-22 1999-09-08 Genentech, Inc. Peptide natriuretique cerebral (bnp) specifique pour un recepteur
AU6820898A (en) 1997-04-04 1998-10-30 Novo Nordisk A/S Natriuretic peptide derivatives
US20040005669A1 (en) * 1997-08-07 2004-01-08 Stefan Stahl Recombinant expression of insulin C-peptide
GB9716790D0 (en) 1997-08-07 1997-10-15 Creative Peptides Sweden Ab Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
CN1149396C (zh) 1997-10-24 2004-05-12 盐野义制药株式会社 利尿钠肽分解抑制方法及其用该方法分析利尿钠肽的改良方法
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
EP1950224A3 (fr) * 1998-03-09 2008-12-17 Zealand Pharma A/S Conjugués peptides pharmacologiquement actifs dotés d'une tendance réduite à l'hydrolyse enzymatique
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
SE9802946D0 (sv) 1998-09-02 1998-09-02 Europrofil Ab Förfarande och listarrangemang för att täcka skarvar eller skapa övergångar i samband med ytbeläggningar
JP3799465B2 (ja) * 1998-09-28 2006-07-19 参天製薬株式会社 ナトリウム利尿ペプチドを有効成分とする涙液分泌促進または角結膜障害治療用点眼剤
ES2180511T3 (es) 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
PT1105409E (pt) * 1999-05-17 2006-07-31 Conjuchem Inc Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue
AU5043900A (en) 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6610043B1 (en) * 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US7127290B2 (en) 1999-10-01 2006-10-24 Cardiac Pacemakers, Inc. Cardiac rhythm management systems and methods predicting congestive heart failure status
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP4237375B2 (ja) * 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
ES2254470T3 (es) * 2000-08-29 2006-06-16 Nobex Corporation Compuestos inmunorreguladores, derivados de los mismos y su uso.
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
FR2823993B1 (fr) * 2001-04-27 2003-06-20 Rhodia Chimie Sa Dispersion colloidale aqueuse stable, son procede de preparation
DE60233301D1 (de) * 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6737913B2 (en) * 2001-06-15 2004-05-18 Silicon Laboratories, Inc. Differential mode circuitry and method of calibrating same without matched external current sources
PT1430082E (pt) 2001-09-07 2010-01-15 Biocon Ltd Métodos de síntese de conjugados de polipéptido de insulina-oligómero, e conjugados de polipéptido de pró-insulina-oligómero e método de síntese dos mesmos
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP1490683A2 (fr) * 2002-03-18 2004-12-29 Scios Inc. Traitement de l'insuffisance cardiaque congestive au moyen d'un peptide natriuretique et d'un diuretique
EP1530588A2 (fr) 2002-07-31 2005-05-18 Conjuchem, Inc. Derives de peptide natriuretique de longue duree
WO2004043396A2 (fr) 2002-11-09 2004-05-27 Nobex Corporation Promedicaments contenant du carbamate modifie et methodes de synthese de ces derniers
CA2504287A1 (fr) 2002-11-26 2004-06-10 Nobex Corporation Composes natriuretiques modifies, leurs conjugues et leur utilisation
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest

Also Published As

Publication number Publication date
CN100558398C (zh) 2009-11-11
DE60331584D1 (de) 2010-04-15
WO2004047871A3 (fr) 2005-03-17
JP2006515579A (ja) 2006-06-01
WO2004047871A2 (fr) 2004-06-10
AU2010201455A1 (en) 2010-05-06
BR0316560A (pt) 2005-10-04
EP1569683A2 (fr) 2005-09-07
AU2003297583B2 (en) 2010-01-14
CA2504287A1 (fr) 2004-06-10
SG159387A1 (en) 2010-03-30
US20040203081A1 (en) 2004-10-14
PL377813A1 (pl) 2006-02-20
CN1741814A (zh) 2006-03-01
EP1569683B1 (fr) 2010-03-03
AU2003297583A1 (en) 2004-06-18
US7662773B2 (en) 2010-02-16
ATE459370T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
HK1087327A1 (en) Modified natriuretic compounds, conjugates, and uses thereof
WO2005116655A3 (fr) Composes natriuretiques, leurs conjugues, et utilisation de ceux-ci
WO2006076471A3 (fr) Conjugues bnp et procedes d'utilisation
JP6026993B2 (ja) 新規のグルカゴンアナログ
WO2003103572A3 (fr) Analogues modifies du peptide-1 de type glucagon (glp-1)
WO2005058958A3 (fr) Nouveaux analogues glp-1 lies a des agents de type albumine
KR20090098843A (ko) 신규 화합물 및 식습관에 대한 이의 효과
JP6383667B2 (ja) 生理活性ポリペプチド複合体の製造のための改善工程
RU2014129893A (ru) Фармацевтическая композиция и способ лечения связанных с гормоном роста заболеваний у человека
RU2012109553A (ru) Модифицированные вазоактивные интестинальные пептиды
RU2009105696A (ru) N-концевое полисиалилирование
WO2009158704A3 (fr) Agents thérapeutiques comprenant des peptides de type élastine
HUE030373T2 (en) A method for producing a site-specific conjugate of a physiologically active polypeptide
EP3495384A1 (fr) Dérivé acylé de l'insuline humaine ou son analogue
JP2008500375A5 (fr)
EP2107069A3 (fr) Nouveaux dérivés d'insuline
ZA200202520B (en) C-peptide for the improved production of insulin and insulin analogues.
KR102185311B1 (ko) 인슐린 위치 특이적 결합체
ZA200508063B (en) Peptides for use in treating obersity
WO2003076585A3 (fr) Modulation controlee de la longueur de chaine laterale des acides amines des antigenes peptides
EP2275439A3 (fr) Nouveaux dérivés d'insuline
BRPI0506694A (pt) análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
TW200502251A (en) Natriuretic compound conjugates, conjugates, and uses thereof
HK1076601A1 (en) Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon
CA2529449A1 (fr) Composition pharmaceutique

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131112